Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 691 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Headache Clear all
Recruiting No phase listed Observational

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

NCT05046613
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Not taking Rimegepant
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older · Female only
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Caffeine/Propranolol Intervention for Acute Migraine

NCT01080677
View directory record Official record
Conditions
Migraine Disorders
Interventions
caffeine/propranolol combination tablet, placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 10, 2026, 9:46 PM EDT
Recruiting Not applicable Interventional

Effect of Ultrasound-Guided Dry Needling Targeting Rectus Capitus Posterior Major on Individuals With Headaches

NCT07309874
View directory record Official record
Conditions
Headache Disorders, Primary, Headache, Cervicogenic
Interventions
Dry needling
Other
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache

NCT02423408
View directory record Official record
Conditions
Tension-Type Headache
Interventions
TNX-201, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
San Jose, California • DeLand, Florida • Stockbridge, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 10, 2026, 9:46 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Headache Chronification With Imaging, Deep Phenotyping, and Proteomics

NCT03231241
View directory record Official record
Conditions
Chronic Daily Headache, Chronic Migraine
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT01952574
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Long Beach, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 10, 2026, 9:46 PM EDT
Terminated Phase 2 Interventional

The Effect of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine

NCT01253915
View directory record Official record
Conditions
Migraine
Interventions
Nasal Carbon Dioxide, Placebo
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
San Diego, California • Bethesda, Maryland • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

NCT04845178
View directory record Official record
Conditions
Migraine
Interventions
ABP-450, Placebo
Drug
Lead sponsor
AEON Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 10, 2026, 9:46 PM EDT
Active, not recruiting No phase listed Observational

Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

NCT05198245
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Various, No intervention
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 49 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1

NCT06462781
View directory record Official record
Conditions
Refractory Migraine
Interventions
Lidocaine hydrochloride, Methylprednisolone sodium succinate
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 10, 2026, 9:46 PM EDT
Not listed No phase listed Observational

Validating a Modified COMPASS 31questionnaire for Treatment Outcomes

NCT05302479
View directory record Official record
Conditions
Headache, Migraine, Persistent Post Traumatic Headache, Cervicogenic Headache
Interventions
COMPASS 31 questionnaire
Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

Metformin for the Prevention of Episodic Migraine (MPEM)

NCT02593097
View directory record Official record
Conditions
Migraine
Interventions
Metformin, Matching Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

NCT00156910
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers

NCT04969497
View directory record Official record
Conditions
Migraine
Interventions
Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

NCT05064397
View directory record Official record
Conditions
Chronic Cluster Headache
Interventions
Eptinezumab
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Stamford, Connecticut • Ann Arbor, Michigan • Amherst, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine

NCT00385008
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Product (sumatriptan succinate / naproxen sodium), RELPAX(eletriptan) 40mg Tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Not applicable Interventional

EMG Biofeedback Treatment for Chronic Low Back Pain, Cancer Pain and Migraines

NCT04607460
View directory record Official record
Conditions
Chronic Low-back Pain, Mastectomy, Lumpectomy, Migraine
Interventions
JOGO Digital Therapeutics EMG Biofeedback for Lower Back Pain, JOGO Digital Therapeutics EMG Biofeedback for Persistent Post Mastectomy Pain, JOGO Digital Therapeutics EMG Biofeedback for Migraine
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine

NCT02057315
View directory record Official record
Conditions
Migraine Headaches
Interventions
ELS-M11, Placebo
Drug
Lead sponsor
Achelios Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Ann Arbor, Michigan • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 10, 2026, 9:46 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Aspirin Resistance in Women With Migraine

NCT01257893
View directory record Official record
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Aspirin (acetylsalicylic acid), Placebo
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 10, 2026, 9:46 PM EDT
Not listed Phase 2Phase 3 Interventional

MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant

NCT00283738
View directory record Official record
Conditions
Migraine, Aura, Patent Foramen Ovale
Interventions
BioSTAR Septal Repair Implant System, Sham Procedure
Device · Procedure
Lead sponsor
NMT Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Stamford, Connecticut • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 25, 2008 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 3 Interventional

A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.

NCT00195754
View directory record Official record
Conditions
Migraines
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2007 · Synced Oct 10, 2026, 9:46 PM EDT
Completed No phase listed Observational

Patent Foramen Ovale in Children With Migraine Headaches

NCT00750594
View directory record Official record
Conditions
Migraine Headaches
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Not applicable Interventional

Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care

NCT03537573
View directory record Official record
Conditions
Acute Pain, Headache, Musculoskeletal Pain
Interventions
Usual Care/Guideline, Opioid Justification, Provider Comparison
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
22,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 10, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine

NCT02389829
View directory record Official record
Conditions
Migraine
Interventions
Hydromorphone, Prochlorperazine, Diphenhydramine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 10, 2026, 9:46 PM EDT